4D Molecular Therapeutics Inc (FDMT)
25.31
-0.33
(-1.29%)
USD |
NASDAQ |
May 17, 16:00
25.31
0.00 (0.00%)
After-Hours: 20:00
4D Molecular Therapeutics Cash from Investing (TTM): -190.67M for March 31, 2024
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -190.67M |
| December 31, 2023 | 115.72M |
| September 30, 2023 | 86.62M |
| June 30, 2023 | 72.01M |
| March 31, 2023 | 80.19M |
| December 31, 2022 | -17.05M |
| September 30, 2022 | -13.56M |
| Date | Value |
|---|---|
| June 30, 2022 | -167.94M |
| March 31, 2022 | -226.15M |
| December 31, 2021 | -172.68M |
| September 30, 2021 | -140.90M |
| June 30, 2021 | -1.538M |
| March 31, 2021 | -0.921M |
| December 31, 2020 | -1.00M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-226.15M
Minimum
Mar 2022
115.72M
Maximum
Dec 2023
-41.28M
Average
-7.55M
Median
Cash from Investing (TTM) Benchmarks
| Ionis Pharmaceuticals Inc | 187.62M |
| NovaBay Pharmaceuticals Inc | 1.062M |
| Palatin Technologies Inc | 9.41M |
| iBio Inc | 8.285M |
| Theriva Biologics Inc | -0.194M |